Page 848 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

826 Index

I Immunotherapy (Continued) Integrative medicine, 330
IACUCs. see Institutional Animal Care and tumor volume reduction and, 169 Integrative oncology, 330–339
approaches in, 331–336
Use Committees
using adoptive T-cell transfer, 241–242
VetBooks.ir IER. see Illness energy requirement using recombinant cytokine therapy, acupuncture, 331
237–238
Ifosfamide, 191
botanical medicine, 331–335
IHC. see Immunohistochemistry interleukin-2, 237–238 homeopathy, 335
IKA. see Infundibular keratinizing acanthoma interleukin-12, 238 massage, 335–336
Illness energy requirement (IER), 304 interleukin-15, 238 photobiomodulation (laser therapy), 336
ILP. see Isolated limb perfusion Immunotoxin, 241 definition of, 330–331
Image-guided biopsy, 161 Implanted device, 17 goals of, 330
Image-guided needle core biopsy, 159 Imprinting, of specimen, 127 integrative medicine into, 330
Imatinib (Gleevec), 262 IMRT. see Intensity-modulated radiotherapy Integrin, 53
for cutaneous feline mast cell tumor, 395 In situ, 63 Intensity-modulated radiotherapy (IMRT),
IMHA. see Immune-mediated hemolytic In situ squamous cell carcinoma, removal of, 169
anemia 170–171 for canine sinonasal tumors, 500
Imiquimod cream, 357 In situ tumor, 40 Interferon, 24
Immortalization, 6 In vitro colony-forming assay, 50 Interferon-α, 238
Immune activation, strategies to control Incidence rate, 82t Interferon-β, 238
tumor growth through, 235–238 Incidental adrenal masses, 575 Interferon-γ, dendritic cell vaccination and,
Immune inflammatory cell, 50 Incidentaloma, 575 238
Immune-mediated hemolytic anemia Incisional biopsy Interferon-ω, 238
(IMHA), 102 diagram of, 161f Interleukin-2 (IL-2), in gross metastatic
Immune-mediated thrombocytopenia (ITP), tract, 167 disease, 547
104 Indirect lymphography, biopsy and, 161–162 Interleukin 12, 238
Immune system Indoleamine 1 (IDO1) expression, 233–234 Interleukin-15, 238
cancer control by, 231–234 INDs. see Investigational new drugs Intermuscular lipoma, 407, 407f
modification to treat cancer, 54 Inductive fibroameloblastoma, 447 Internal margin, 215–216
role of, 231 Inductive odontogenic tumor, 447 Internal tandem duplication
tumor control by, 231–234 Inefficiency, in metastatic process, 55 detection of, 148
tumor destruction by, 9, 10f Infiltrative lipoma, 407–408, 407f in FLT3 gene, 148
tumor evasion of, 53–54, 232f Inflammation Internal tandem duplication (ITD), mutations
mechanisms of, 231–234 neoplasia versus, 63 and, 259–260
tumor failure to activate, 233–234 as physical carcinogen, 16 Internal validity, 82t
Immunocytochemical staining, 129 reactive fibroblasts and endothelial cells, 63 Interphase, 36
Immunoediting hypothesis, 231 tumor-promoting, 7–8, 49 Interpretation error, 75
Immunoglobulin gene, 150f Inflammatory mammary carcinoma, 287t, Interstitial cell tumor
Immunoglobulin heavy chain locus, 6 607f characteristics of, 627t
Immunohistochemistry (IHC) Informed consent hormone levels in, 628–629
complicating factors of, 71–74 in clinical trial, 348 pathology and pathogenesis of, 627
indications for, 71 elements of, 348b Interventional oncology, 174–181
procedure for, 151 Infundibular keratinizing acanthoma (IKA), imaging of, 174
Immunostimulatory cytokines, 239 358 instrumentation of, 174–175
Immunosuppression Inhibin-α(INH−α), 597 principles of, 174–175
MDSCs to decrease, 235t Inhibitory protein, CDK inhibitors as, 36–37 treatment categories, 175–180
by myeloid-derived suppressor cells, 233 Injection-site sarcomas, 93, 418–425 ablation, 179–180, 179f
skin cancer and, 353–354 INK4 tumor suppressor locus, 10 drainage, 180
Immunosuppressive cytokine, production of, INK4A family, 37 embolization and chemoembolization,
234 Inking system, for indicating margins, 162 177–179
Immunosuppressor barrier, 9 Insecticide, 15 intraarterial chemotherapy, 176–177
Immunosurveillance theory, 53 Institutional Animal Care and Use stenting of malignant strictures,
of cancer, 231 Committees (IACUCs), 348 175–176
Immunotherapy, 231–250 Institutional Review Board (IRB), 344 Intestinal anastomosis, 170
for cancer, 239–240 Insulin growth factor-1 (IGF-1), 98 Intestinal carcinoid, 585
for canine osteosarcoma, 544–545 Insulin growth factor-2 (IGF-2) gene, 10 Intestinal tumors, 460
cytokine activity in, 234t–235t Insulin therapy, for feline acromegaly, 571 clinical pathology for, 463
gene-directed, 256 Insulin-like growth factor, canine comparative aspects of, 467–468
goals of, 239 osteosarcoma and, 526 diagnostic technique for, 463–465
interferons and, 238 Insulin-like growth factor-1 (IGF-1), in feline imaging, 463–465
with live attenuated Salmonella, 236 acromegaly, 569 physical examination in, 463
monoclonal antibodies and, 240–241, 241t Insulinomas, 582–584 history and clinical signs of, 462–463
natural killer cell, 242 characteristics of, 137 paraneoplastic syndromes, 463
for oral melanoma, 374–376 hypoglycemia and, 101 imaging for, 463–465